Trials / Completed
CompletedNCT02180763
Gammanorm Quality of Life Study in Immunodeficient Patients Using Rapid Push or Pumps
A Randomized, Cross-over Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL According to the Delivery Device: Injections Using Pump or Rapid Push.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Octapharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare satisfaction (LQI questionnaire, factor I: treatment interference) in PID patients receiving subcutaneous injections of Gammanorm® 165 mg/mL according to the delivery device.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Gammanorm | Sub-Q IgG |
Timeline
- Start date
- 2014-04-01
- Primary completion
- 2016-08-28
- Completion
- 2017-08-26
- First posted
- 2014-07-03
- Last updated
- 2018-09-05
Locations
8 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02180763. Inclusion in this directory is not an endorsement.